Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories.

Sommer JM, Moore N, McGuffie-Valentine B, Bardan S, Buyue Y, Kamphaus GD, Konkle BA, Pierce GF.

Haemophilia. 2014 Mar;20(2):294-300. doi: 10.1111/hae.12296. Epub 2013 Nov 22.

2.

A world-wide survey and field study in clinical haemostasis laboratories to evaluate FVIII:C activity assay variability of ADYNOVATE and OBIZUR in comparison with ADVATE.

Turecek PL, Romeder-Finger S, Apostol C, Bauer A, Crocker-Buqué A, Burger DA, Schall R, Gritsch H.

Haemophilia. 2016 Nov;22(6):957-965. doi: 10.1111/hae.13001. Epub 2016 Jun 28.

PMID:
27353010
3.

Factor VIII assay variability in postinfusion samples containing full length and B-domain deleted FVIII.

Kitchen S, Jennings I, Makris M, Kitchen DP, Woods TA, Walker ID.

Haemophilia. 2016 Sep;22(5):806-12. doi: 10.1111/hae.12962. Epub 2016 May 24.

PMID:
27217329
4.
5.

International comparative field study of N8 evaluating factor VIII assay performance.

Viuff D, Barrowcliffe T, Saugstrup T, Ezban M, Lillicrap D.

Haemophilia. 2011 Jul;17(4):695-702. doi: 10.1111/j.1365-2516.2010.02481.x. Epub 2011 Mar 22.

PMID:
21426445
6.

Comparative field study: impact of laboratory assay variability on the assessment of recombinant factor IX Fc fusion protein (rFIXFc) activity.

Sommer JM, Buyue Y, Bardan S, Peters RT, Jiang H, Kamphaus GD, Gray E, Pierce GF.

Thromb Haemost. 2014 Nov;112(5):932-40. doi: 10.1160/TH13-11-0971. Epub 2014 Aug 21.

PMID:
25144892
7.

Biochemical and functional characterization of a recombinant monomeric factor VIII-Fc fusion protein.

Peters RT, Toby G, Lu Q, Liu T, Kulman JD, Low SC, Bitonti AJ, Pierce GF.

J Thromb Haemost. 2013 Jan;11(1):132-41. doi: 10.1111/jth.12076.

8.

A multicenter pharmacokinetic study of the B-domain deleted recombinant factor VIII concentrate using different assays and standards.

Morfini M, Cinotti S, Bellatreccia A, Paladino E, Gringeri A, Mannucci PM; ReFacto-AICE Study Group..

J Thromb Haemost. 2003 Nov;1(11):2283-9. Erratum in: J Thromb Haemost. 2004 Feb;2(2):382.

9.

Performance of recalibrated ReFacto laboratory standard in the measurement of FVIII plasma concentration via the chromogenic and one-stage assays after infusion of recalibrated ReFacto (B-domain deleted recombinant factor VIII).

Santoro C, Iorio A, Ferrante F, Pallotta A, Pignoloni P, Biondo F, Agnelli G, Mazzucconi MG.

Haemophilia. 2009 May;15(3):779-87. doi: 10.1111/j.1365-2516.2009.01983.x. Epub 2009 Feb 27.

PMID:
19298379
10.

A single chain variant of factor VIII Fc fusion protein retains normal in vivo efficacy but exhibits altered in vitro activity.

Buyue Y, Liu T, Kulman JD, Toby GG, Kamphaus GD, Patarroyo-White S, Lu Q, Reidy TJ, Mei B, Jiang H, Pierce GF, Sommer JM, Peters RT.

PLoS One. 2014 Nov 21;9(11):e113600. doi: 10.1371/journal.pone.0113600. eCollection 2014.

11.

A critical appraisal of one-stage and chromogenic assays of factor VIII activity.

Peyvandi F, Oldenburg J, Friedman KD.

J Thromb Haemost. 2016 Feb;14(2):248-61. doi: 10.1111/jth.13215. Epub 2016 Feb 1. Review.

PMID:
26663865
12.

A blinded in vitro study with Refacto mock plasma samples: similar FVIII results between the chromogenic assay and a one-stage assay when using a higher cephalin dilution.

Caron C, Dautzenberg MD, Delahousse B, Droulle C, Pouzol P, Dubanchet A, Rothschild C.

Haemophilia. 2002 Sep;8(5):639-43.

PMID:
12199672
13.

The use of the new ReFacto AF Laboratory Standard allows reliable measurement of FVIII:C levels in ReFacto AF mock plasma samples by a one-stage clotting assay.

Pouplard C, Caron C, Aillaud MF, Ternisien C, Desconclois C, Dubanchet A, Sobas F.

Haemophilia. 2011 Sep;17(5):e958-62. doi: 10.1111/j.1365-2516.2011.02523.x. Epub 2011 Apr 4. Erratum in: Haemophilia. 2012 Jan;18(1):e42.

PMID:
21457408
14.

Assaying the circulating factor VIII activity in hemophilia A patients treated with recombinant factor VIII products.

Mikaelsson M, Oswaldsson U.

Semin Thromb Hemost. 2002 Jun;28(3):257-64. Review.

PMID:
12098085
15.

Coagulation and chromogenic assays of factor VIII activity: general aspects, standardization, and recommendations.

Barrowcliffe TW, Raut S, Sands D, Hubbard AR.

Semin Thromb Hemost. 2002 Jun;28(3):247-56. Review.

PMID:
12098084
16.

One-stage vs. chromogenic assays in haemophilia A.

Potgieter JJ, Damgaard M, Hillarp A.

Eur J Haematol. 2015 Feb;94 Suppl 77:38-44. doi: 10.1111/ejh.12500. Review.

PMID:
25560793
17.

A computer-based model to assess costs associated with the use of factor VIII and factor IX one-stage and chromogenic activity assays.

Kitchen S, Blakemore J, Friedman KD, Hart DP, Ko RH, Perry D, Platton S, Tan-Castillo D, Young G, Luddington RJ.

J Thromb Haemost. 2016 Apr;14(4):757-64. doi: 10.1111/jth.13253. Epub 2016 Feb 18.

PMID:
26748742
18.

Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A.

Young G, Mahlangu J, Kulkarni R, Nolan B, Liesner R, Pasi J, Barnes C, Neelakantan S, Gambino G, Cristiano LM, Pierce GF, Allen G.

J Thromb Haemost. 2015 Jun;13(6):967-77. doi: 10.1111/jth.12911. Epub 2015 Apr 23.

PMID:
25912075
19.

Reproducibility of one-stage, two-stage and chromogenic assays of factor VIII activity: a multi-center study.

Cinotti S, Longo G, Messori A, Morfini M, Blomback M, Schimpf K, Schumacher K, Kjellman H, Novakova-Banet A, Delvos U.

Thromb Res. 1991 Feb 15;61(4):385-93.

PMID:
1905848

Supplemental Content

Support Center